Nandini Verma
Affiliations: | Molecular Cell Biology | Weizmann Institute of Science, Rehovot, Israel |
Google:
"Nandini Verma"
BETA: Related publications
See more...
Publications
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
Verma N, Vinik Y, Saroha A, et al. (2020) Synthetic lethal combination targeting BET uncovered intrinsic susceptibility of TNBC to ferroptosis. Science Advances. 6 |
Kumar R, George B, Campbell MR, et al. (2020) HER family in cancer progression: From discovery to 2020 and beyond. Advances in Cancer Research. 147: 109-160 |
Verma N, Müller AK, Kothari C, et al. (2020) Correction: Targeting of PYK2 Synergizes with EGFR Antagonists in Basal-like TNBC and Circumvents HER3-Associated Resistance via the NEDD4-NDRG1 Axis. Cancer Research. 80: 362 |
Kedan A, Verma N, Saroha A, et al. (2018) PYK2 negatively regulates the Hippo pathway in TNBC by stabilizing TAZ protein. Cell Death & Disease. 9: 985 |
Shin SY, Müller AK, Verma N, et al. (2018) Systems modelling of the EGFR-PYK2-c-Met interaction network predicts and prioritizes synergistic drug combinations for triple-negative breast cancer. Plos Computational Biology. 14: e1006192 |
Verma N, Müller AK, Kothari C, et al. (2016) Targeting of PYK2 synergizes with EGFR antagonists in basal-like TNBC and circumvents HER3-associated resistance via the NEDD4-NDRG1 axis. Cancer Research |
Verma N, Keinan O, Selitrennik M, et al. (2015) PYK2 sustains endosomal-derived receptor signalling and enhances epithelial-to-mesenchymal transition. Nature Communications. 6: 6064 |